Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
- 1 July 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (7) , 2170-2180
Abstract
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is an important member of the tumor necrosis factor subfamily with great potential in cancer therapy. Andrographolide (Andro), a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, is known to possess potent anti-inflammatory and anticancer activities. Here, we showed that pretreatment with Andro significantly enhances TRAIL-induced apoptosis in various human cancer cell lines, including those TRAIL-resistant cells. Such sensitization is achieved through transcriptional up-regulation of death receptor 4 (DR4), a death receptor of TRAIL. In search of the molecular mechanisms responsible for DR4 up-regulation, we found that the tumor suppressor p53 plays an essential role in DR4 transcriptional activation. Andro is capable of activating p53 via increased p53 phosphorylation and protein stabilization, a process mediated by enhanced reactive oxygen species production and subsequent c-Jun NH2-terminal kinase activation. Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH2-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis. Taken together, these results present a novel anticancer effect of Andro and support its potential application in cancer therapy to overcome TRAIL resistance. [Mol Cancer Ther 2008;7(7):2170–80]Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- TRAIL death receptors and cancer therapeuticsToxicology and Applied Pharmacology, 2007
- TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2British Journal of Haematology, 2007
- Andrographolide Inhibits Human Hepatoma-Derived Hep3B Cell Growth through the Activation of c-Jun N-Terminal KinasePlanta Medica, 2007
- Barriers to Effective TRAIL-Targeted Therapy of MalignancyJournal of Clinical Oncology, 2007
- Targeting death-inducing receptors in cancer therapyOncogene, 2007
- The clinical trail of TRAILEuropean Journal of Cancer, 2006
- Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Resistant Bladder Tumor CellsCancer Research, 2006
- Down-regulation of c-FLIP contributes to the sensitization effect of 3,3′-diindolylmethane on TRAIL-induced apoptosis in cancer cellsMolecular Cancer Therapeutics, 2005
- Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death & Differentiation, 2004
- Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2004